Codexis, Inc. (CDXS)

Market Cap	259.56M
Revenue (ttm)	74.23M
Net Income (ttm)	-65.13M
Shares Out	70.56M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	138.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,419
Open	3.840
Previous Close	3.650
Day's Range	3.650 - 3.840
52-Week Range	1.450 - 4.910
Beta	2.05
Analysts	Strong Buy
Price Target	7.50 (+105.48%)
Earnings Date	May 2, 2024

About CDXS

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS

Financial Performance

In 2023, Codexis's revenue was $70.14 million, a decrease of -49.39% compared to the previous year's $138.59 million. Losses were -$76.24 million, 127.0% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CDXS stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 105.48% from the latest price.

Price Target

$7.5

(105.48% upside)

Analyst Consensus: Strong Buy